Drospirenone is owned by Exeltis Usa Inc.
Drospirenone contains Drospirenone.
Drospirenone has a total of 13 drug patents out of which 0 drug patents have expired.
Drospirenone was authorised for market use on 29 June, 2022.
Drospirenone is available in tablet, chewable;oral dosage forms.
Drospirenone can be used as prevention of pregnancy in females of reproductive age.
The generics of Drospirenone are possible to be released after 28 June, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(8 years from now) | |
US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) | |
US11478487 | EXELTIS USA INC | NA |
Jun, 2031
(8 years from now) | |
US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET, CHEWABLE;ORAL
19
United States
5
European Union
4
Korea, Republic of
4
Lithuania
4
Hungary
3
Canada
3
Guatemala
3
Mexico
3
Ecuador
2
Spain
2
Denmark
2
RS
2
Poland
2
Brazil
2
Croatia
2
Peru
2
Portugal
2
Slovenia
1
Argentina
1
EA
1
Norway
1
Japan
1
New Zealand
1
Cyprus
1
Chile
1
Australia
1
South Africa
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic